Pharmacists Association warns FDA against premature peptide approval

Brigid Groves, the association's vice president of professional affairs, emphasizes that while innovation is vital, it must remain grounded in rigorous scientific standards. Pharmacists currently lack the necessary data regarding the safety profiles and long-term effects of these substances to provide reliable patient counseling. By opposing the immediate expansion of the Bulks List, the group aims to curb the influence of black-market suppliers that operate outside traditional regulatory safeguards.

Instead of broad approval, the association is calling for intensified research and enhanced collaboration between the FDA, state pharmacy boards, and the United States Pharmacopeia. They argue that if future peer-reviewed studies establish safety, compounding pharmacists could eventually play a key role in delivering these therapies through regulated channels. For now, the group insists that protecting public health requires prioritizing established clinical evidence over the rapid proliferation of unverified products.